Abstract: Objective　To analyze and evaluate the effects and safety of magnesium sulfate combined with ligustrazine on treatment of pregnancy-induced hypertension compared with monotherapy of magnesium sulfate by meta-analysis,and to provide evidence for clinical medication decisions.Methods　A computer-based retrieval of CNKI,CBM,Wanfang Data,VIP,China Dissertation Database,Cochrane Library,PubMed,EMBase,OVID,EBSCO were made,and relevant literatures of research group adopting magnesium sulfate combined with ligustrazine,and of control group only using magnesium sulfate in treating pregnancy-induced hypertension were screened.The searching period was from the time of database building to December 2015.The abstracts of literatures were read and literatures were screened of the full text,and necessary data were extracted and induced,including the first author,publishing time,sample size,intervening measures,courses of treatment,outcome indicators,as well as random method,allocation concealment and blinding methods,and other sources of bias;the quality of the included literatures was assessed according to the standard form of quality assessment of Cochrane Handbook for Systematic Reviews of Interventions（5.1.0 version）.The total effective rate，incidence of postpartum hemorrhage，incidence of neonatal asphyxia，incidence of fetal distress，and incidence of adverse reactions between the two groups were analyzed using RevMan 5.3 software.Results　A total of 16 literatures were enrolled,including 1 369 patients,of which 683 in control group and 686 in research group.13 literatures were randomly divided into groups,of which only one had mentioned the method of blinding in observing and evaluating outcome indicators;allocation concealment were not reported in all the included literatures,and no lost to follow-up and selective reports results were found,and research data were completely provided.The results of meta analysis were shown as follows:compared with control group,the total effective rate of research group was higher〔RR=1.19,95%CI（1.13,1.25）〕,incidence of postpartum hemorrhage〔RR=0.38,95%CI（0.25,0.58）〕,incidence of neonatal asphyxia〔RR=0.35,95%CI（0.21,0.58）〕,and the incidence of fetal distress in uterus〔RR=0.42,95%CI（0.26,0.66）〕,and incidence of adverse reactions〔RR=0.30,95%CI（0.15,0.57）〕 were lower.ConclusionMagnesium sulfate combined with ligustrazine in the treatment of pregnancy-induced hypertension is superior to using magnesium sulfate alone in terms of the following aspects:improving overall clinical efficiency,and reducing rates of postpartum hemorrhage,neonatal asphyxia,fetal distress in uterus,and adverse reactions.

Key words: Hypertension,pregnancy-induced, Magnesium sulfate, Tetramethylpyrazine, Treatment outcome, Drug toxicity, Meta-analysis

摘要： 目的　采用Meta分析评价硫酸镁联合川芎嗪对比硫酸镁单药治疗妊娠期高血压的有效性及安全性，为临床用药决策提供循证证据。方法　计算机检索中国知网、中国生物医学文献数据库、万方数据知识服务平台、维普期刊资源整合服务平台、中国学位论文全文数据库、Cochrane Library、PubMed、EMBase、OVID、EBSCO等数据库，筛选研究组采用硫酸镁联合川芎嗪，对照组仅采用硫酸镁治疗妊娠期高血压的相关文献，检索年限均从建库至2015年12月。阅读文献摘要及全文筛选文献，提取归纳所需资料，包括第一作者、发表时间、样本量、干预措施、疗程、结局指标，以及随机方法、分配隐藏及盲法、其他偏倚来源等；按Cochrane系统评价员手册（5.1.0版）的质量评价标准表格对纳入文献进行质量评价。采用RevMan 5.3软件分析两组总有效率、产后出血发生率、新生儿窒息发生率、胎儿宫内窘迫发生率及不良反应发生率。结果　共纳入16篇文献，共1 369例患者，对照组683例，研究组686例。13篇文献为随机分组，仅有1篇文献提及采用盲法对结局指标进行观察评估，纳入文献均未报道分配隐藏及方法，均无失访报道和选择性报告结果，均完整提供了研究数据。Meta分析结果显示，研究组总有效率高于对照组〔RR=1.19,95%CI（1.13,1.25）〕，产后出血发生率〔RR=0.38，95%CI（0.25，0.58）〕、新生儿窒息发生率〔RR=0.35，95%CI（0.21，0.58）〕、胎儿宫内窘迫发生率〔RR=0.42，95%CI（0.26，0.66）〕、不良反应发生率〔RR=0.30，95%CI（0.15，0.57）〕低于对照组。结论　硫酸镁联合川芎嗪治疗妊娠期高血压在提高临床总有效率，降低产后出血、新生儿窒息、胎儿宫内窘迫、不良反应发生率方面均优于单用硫酸镁。

关键词: 高血压,妊娠性, 硫酸镁, 川芎嗪, 治疗结果, 药物毒性, Meta分析